Tocilizumab in patients infected by SARS-CoV2.
作者信息
Sancho Milagros, Muñiz Javier, Cardinal-Fernández Pablo
机构信息
Unidad de Cuidados Intensivos, Hospital Universitario Gregorio Marañón, Madrid, Spain.
Departamento de Ciencias de la Salud, Universidad de A Coruña, Spain.
出版信息
Med Clin (Engl Ed). 2021 Apr 23;156(8):402-406. doi: 10.1016/j.medcle.2020.12.010. Epub 2021 Mar 19.
Abstract
摘要
相似文献
1
Tocilizumab in patients infected by SARS-CoV2.
Med Clin (Engl Ed). 2021 Apr 23;156(8):402-406. doi: 10.1016/j.medcle.2020.12.010. Epub 2021 Mar 19.
2
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
3
Tocilizumab: From Rheumatic Diseases to COVID-19.
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
4
Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.
Biochem Biophys Res Commun. 2021 Jan 29;538:151-155. doi: 10.1016/j.bbrc.2020.11.084. Epub 2020 Nov 28.
5
Host-virus chimeric events in SARS-CoV2 infected cells are infrequent and artifactual.
bioRxiv. 2021 Feb 17:2021.02.17.431704. doi: 10.1101/2021.02.17.431704.
6
SARS-CoV2 Infection During Pregnancy Causes Persistent Immune Abnormalities in Women Without Affecting the Newborns.
Front Immunol. 2022 Jul 14;13:947549. doi: 10.3389/fimmu.2022.947549. eCollection 2022.
7
Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature.
Skelet Muscle. 2021 Apr 21;11(1):10. doi: 10.1186/s13395-021-00266-5.
8
Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study.
Biochim Biophys Acta Mol Basis Dis. 2021 Mar 1;1867(3):166042. doi: 10.1016/j.bbadis.2020.166042. Epub 2020 Dec 16.
9
[Symptoms of SARS-CoV-2 infections in children of day care age].
Monatsschr Kinderheilkd. 2022;170(12):1113-1121. doi: 10.1007/s00112-022-01640-3. Epub 2022 Nov 9.
10
Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
Innate Immun. 2022 Jan;28(1):3-10. doi: 10.1177/17534259211064602. Epub 2022 Jan 28.
引用本文的文献
1
Epidemiology of the COVID-19 pneumonia in a group of hospitals from Madrid-Spain during the full period of the State of Alarm HM cohort.
Rev Esp Quimioter. 2025 Mar 3;38(2):97-107. doi: 10.37201/req/110.2024. Epub 2025 Feb 14.
本文引用的文献
1
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
Crit Care Med. 2022 Mar 1;50(3):398-409. doi: 10.1097/CCM.0000000000005229.
2
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
3
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
4
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
5
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
6
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
7
COVACTA trial raises questions about tocilizumab's benefit in COVID-19.
Lancet Rheumatol. 2020 Oct;2(10):e592. doi: 10.1016/S2665-9913(20)30313-1. Epub 2020 Sep 9.
8
Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis.
Med Clin (Engl Ed). 2020 Aug 28;155(4):143-151. doi: 10.1016/j.medcle.2020.05.004. Epub 2020 Aug 22.
9
Efficacy of tocilizumab treatment in severely ill COVID-19 patients.
Crit Care. 2020 Aug 27;24(1):524. doi: 10.1186/s13054-020-03224-7.
10
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.
Lancet Rheumatol. 2020 Oct;2(10):e603-e612. doi: 10.1016/S2665-9913(20)30277-0. Epub 2020 Aug 14.
Zotero 插件